Table 2.

Relationships between polyunsaturated fatty acids and non‐alcoholic fatty liver disease in patients with type 2 diabetes

	Univariable model		Multivariable model
	OR (95% CI)	P‐value	OR (95% CI)	P‐value
n6 PUFA
Per SD increase	1.43 (1.14–1.79)	0.0019	1.24 (0.97–1.58)	0.0864
≥8,100 vs <8,100 μmol/L	3.24 (1.60–6.55)	0.0011	2.69 (1.27–5.67)	0.0096
n3 PUFA
Per SD increase	1.77 (1.34–2.35)	<0.0001	1.94 (1.49–2.52)	<0.0001
≥800 vs <800 μmol/L	2.66 (1.59–4.43)	0.0002	2.20 (1.28–3.78)	0.0045
n6/n3 ratio
Per SD increase	0.71 (0.58–0.85)	0.0003	0.69 (0.56–0.86)	0.0007
≤10 vs >10	1.92 (1.31–2.82)	0.0008	1.80 (1.20–2.71)	0.0045

Multivariable model was adjusted for age, sex, glycated hemoglobin, systolic blood pressure, duration of diabetes, hypoglycemic drugs and lipid‐lowering drugs.

CI, confidence interval; NAFLD, non‐alcoholic fatty liver disease; OR, odds ratio; PUFA, polyunsaturated fatty acids; SD, standard deviation.